Carbiotix partner growth exceeds goal and expectations

Aug 07, 2020, 08:45

Carbiotix AB (publ) ("Carbiotix") announces today that the company has added three new LinkGut partners in Q2. This far exceeds the company’s previously stated goal of adding five partners between 2021-2023. Moreover, the company sees continued strong interest in its LinkGut service going forward which indicates that the value proposition is very strong and thus has the potential to play a key role in supporting the global roll-out of diagnostics services and growth of Carbiotix modulator sales (AXOS ingredient, medical food and therapeutics). 

LinkGut ( is a white label gut health testing service offered by Carbiotix to food & beverage, supplement and pharmaceutical companies, as well as providers of health & wellness services. The service is entirely free for partners, is both dedicated and fully customisable, and is based on Carbiotix OneGut gut heath testing platform. OneGut is the only consumer gut health test based on triplicate (3 samples), offering both Next Generation Sequencing (NGS) and Polymerase Chain Reaction (PCR) tests, is priced at one third the cost of the nearest competitor on the market on a comparable sample vial basis, facilitates for personalised nutrition, and is focused on longitudinal tracking and key metabolites. The service allows LinkGut partners to build customer loyalty and formulate better products, and their customers to validate the efficacy and personalise their products over time. The LinkGut service allows Carbiotix to significantly reduce customer acquisition costs while expanding channels to market. 


Kristofer Cook, CEO for Carbiotix, comments

"I am very pleased with the growth of our LinkGut partner network in Q2, as adding three new partners far exceeds our original goal and expectations stated in our memorandum from last year. In addition to our previously communicated partners TrooFood, RevivaBio, EONOS and Live Younger, I am happy to welcome Optimising Health (UK), Disc Profiling (UK), and GutHealth (SE). The LinkGut service was specifically developed for companies to offer a dedicated gut health testing service for their customers, embrace transparency, and eventually personalise their food & beverage and supplement products without having to re-engineer production and distribution systems. Moreover, since Carbiotix is also developing its own second-generation prebiotic, each LinkGut partner in the food & beverage and supplement space naturally also becomes a potential customer for this prebiotic given the gut health benefits of Carbiotix corn fiber extract containing AXOS and its competitive price. I am even more encouraged by the level of interest in our LinkGut service to date and the pipeline of potential partners that may land in 2020 H2 and beyond. OneGut has truly to the potential to become a dominant testing platform in a fast-growing market, which should ultimately lead to increasing diagnostic sales and even more important accelerate high margin AXOS and other modulator sales going forward." 
This is information that Carbiotix AB is obliged to make public according to the EU Market Abuse Regulation (MAR). The information was made publicly available by the company’s contact person set out below on 7 August 2020. 
Forward-looking statements
This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

For further information:
Carbiotix AB
Kristofer Cook, CEO
Tel: +46 708-796580

Carbiotix AB (CRBX) ( is an award-winning biotechnology company pioneering microbiome healthcare through a range of cost-effective gut health testing services and a portfolio of microbiome modulators covering prebiotic ingredients, medical foods and therapeutics.

Go Back